Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:HSM NYSE:PHM NASDAQ:TLT CVE:VPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSMHelius Medical TechnologiesC$0.00C$14.26▼C$40.00C$42.54MN/A3,578 shs930 shsPHMPulteGroup$128.82+0.2%$111.76$88.07▼$149.47$25.39B1.222.15 million shs1.92 million shsTLTiShares 20+ Year Treasury Bond ETF$86.40-0.7%$86.72$83.29▼$101.64$48.31B0.0638.83 million shs36.32 million shsVPTVentriPoint DiagnosticsC$0.11-4.3%C$0.13C$0.08▼C$0.21C$17.84M0.39190,785 shs158,700 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSMHelius Medical Technologies0.00%0.00%0.00%0.00%0.00%PHMPulteGroup0.00%+5.91%+17.74%+23.46%+5.70%TLTiShares 20+ Year Treasury Bond ETF0.00%-1.02%+1.52%+0.12%-11.74%VPTVentriPoint Diagnostics0.00%-4.35%-24.14%-12.00%-43.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSMHelius Medical TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APHMPulteGroup4.8423 of 5 stars2.45.02.51.93.51.73.8TLTiShares 20+ Year Treasury Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AVPTVentriPoint DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSMHelius Medical Technologies 0.00N/AN/AN/APHMPulteGroup 2.79Moderate Buy$135.315.04% UpsideTLTiShares 20+ Year Treasury Bond ETF 0.00N/AN/AN/AVPTVentriPoint Diagnostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VPT, TLT, PHM, and HSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025PHMPulteGroupWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$150.007/23/2025PHMPulteGroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$141.00 ➝ $150.007/23/2025PHMPulteGroupCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$128.00 ➝ $132.007/23/2025PHMPulteGroupRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$115.00 ➝ $140.007/23/2025PHMPulteGroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$132.00 ➝ $140.007/23/2025PHMPulteGroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$121.00 ➝ $123.007/23/2025PHMPulteGroupWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$125.00 ➝ $135.007/23/2025PHMPulteGroupRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$109.00 ➝ $112.007/22/2025PHMPulteGroupSeaport Res PtnSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/15/2025PHMPulteGroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$125.00 ➝ $132.00(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSMHelius Medical TechnologiesC$477K0.00N/A5.71C$3.61 per share0.00PHMPulteGroup$17.95B1.42$14.23 per share9.05$63.74 per share2.02TLTiShares 20+ Year Treasury Bond ETFN/AN/AN/AN/AN/AN/AVPTVentriPoint DiagnosticsC$140.67K126.84C$0.02 per share5.53C($0.02) per share-7.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSMHelius Medical TechnologiesN/A-C$11.02N/AN/AN/AN/AN/AN/AN/APHMPulteGroup$3.08B$13.389.639.520.3815.50%21.01%14.73%10/28/2025 (Estimated)TLTiShares 20+ Year Treasury Bond ETFN/AN/AN/A∞N/AN/AN/AN/AN/AVPTVentriPoint Diagnostics-C$5.25M-C$0.03N/A∞N/A-3,732.10%388.60%-136.72%N/ALatest VPT, TLT, PHM, and HSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2025Q2 2025PHMPulteGroup$2.92$3.03+$0.11$3.03$4.42 billion$4.40 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSMHelius Medical TechnologiesN/AN/AN/AN/AN/APHMPulteGroup$0.880.68%N/A6.58%7 YearsTLTiShares 20+ Year Treasury Bond ETF$3.844.44%N/AN/AN/AVPTVentriPoint DiagnosticsN/AN/AN/AN/AN/ALatest VPT, TLT, PHM, and HSM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/31/2025TLTiShares 20+ Year Treasury Bond ETFMonthly$0.33084.52%8/1/20258/1/20258/6/20256/30/2025TLTiShares 20+ Year Treasury Bond ETFMonthly$0.32834.47%7/1/20257/1/20257/7/20255/30/2025TLTiShares 20+ Year Treasury Bond ETFMonthly$0.31954.5%6/2/20256/2/20256/5/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSMHelius Medical Technologies0.744.203.58PHMPulteGroup0.130.770.77TLTiShares 20+ Year Treasury Bond ETFN/AN/AN/AVPTVentriPoint Diagnostics-58.560.286.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSMHelius Medical TechnologiesN/APHMPulteGroup89.90%TLTiShares 20+ Year Treasury Bond ETF73.33%VPTVentriPoint DiagnosticsN/AInsider OwnershipCompanyInsider OwnershipHSMHelius Medical TechnologiesN/APHMPulteGroup0.76%TLTiShares 20+ Year Treasury Bond ETFN/AVPTVentriPoint Diagnostics2.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSMHelius Medical Technologies192.32 millionN/ANot OptionablePHMPulteGroup6,793197.30 million195.80 millionOptionableTLTiShares 20+ Year Treasury Bond ETFN/A559.10 millionN/AOptionableVPTVentriPoint Diagnostics147,000162.20 millionN/ANot OptionableVPT, TLT, PHM, and HSM HeadlinesRecent News About These CompaniesCEO.CA's Inside the Boardroom: Cardiac MRI Alternative Gets FDA Nod - Ventripoint CEO on U.S. and China Sales PlansAugust 13, 2025 | finance.yahoo.comVentripoint Diagnostics Ltd. (VPT.V) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comWhen AI Meets Heart Care: The FDA Just Cleared A Revolutionary Cardiac Imaging Device. Here’s What You Should KnowMarch 15, 2025 | theglobeandmail.comVentriPoint Diagnostics Launches Private Placement to Bolster OperationsMarch 14, 2025 | tipranks.comShares Of AI Company Surging On FDA 510(k) Clearance NewsFebruary 27, 2025 | msn.comVentripoint Diagnostics Announces U.S. FDA 510(k) Clearance for VMS+(TM) 4.0 Automated Radiological Image Processing Software/SystemFebruary 27, 2025 | finance.yahoo.comVentripoint refines AI-powered heart scanner submission to FDAJanuary 21, 2025 | msn.comVentriPoint Completes Second Tranche of Convertible Debenture OfferingJanuary 20, 2025 | tipranks.comVentripoint Issues Shares for Payment of Debenture InterestJanuary 10, 2025 | stockhouse.comVPT:CA Stock PriceNovember 26, 2024 | seekingalpha.comVentripoint Announces New Sales Program to Accelerate Growth in U.S. Market for AI-Powered Echocardiography SolutionsNovember 20, 2024 | stockhouse.comDiagnostic Medical Sonographer SalaryOctober 25, 2024 | money.usnews.comVentripoint Receives EU CE Mark for Next Generation, AI-powered Heart-scanning TechnologyOctober 24, 2024 | finance.yahoo.comVentripoint to debut new AI heart-scanning tech in EuropeOctober 24, 2024 | msn.comThe Evolution of Cardiac Imaging: Impending Market Growth Fuels Innovation; Fusion with AIOctober 24, 2024 | invezz.comIVentriPoint Diagnostics Ltd (VPT)October 4, 2024 | investing.comAI Powered Heart Imaging Solutions Improve Heart Care With a Cheaper, Faster Alternative to MRIsSeptember 25, 2024 | invezz.comIVentripoint Hires ERG to Provide Investor Relations ServicesSeptember 9, 2024 | stockhouse.comVentripoint Issues Option Grants and Reports Exercise of OptionsSeptember 9, 2024 | stockhouse.comVentripoint Diagnostics Ltd. (VPT.V)September 3, 2024 | nz.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVPT, TLT, PHM, and HSM Company DescriptionsHelius Medical Technologies TSE:HSMHelius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.PulteGroup NYSE:PHM$128.82 +0.27 (+0.21%) Closing price 08/15/2025 03:59 PM EasternExtended Trading$131.41 +2.59 (+2.01%) As of 08/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PulteGroup, Inc., through its subsidiaries, primarily engages in the homebuilding business in the United States. It acquires and develops land primarily for residential purposes; and constructs housing on such land. The company also offers various home designs, including single-family detached, townhomes, condominiums, and duplexes under the Centex, Pulte Homes, Del Webb, DiVosta Homes, John Wieland Homes and Neighborhoods, and American West brand names. In addition, the company arranges financing through the origination of mortgage loans primarily for homebuyers; sells the servicing rights for the originated loans; and provides title insurance policies, and examination and closing services to homebuyers. PulteGroup, Inc. was founded in 1950 and is headquartered in Atlanta, Georgia.iShares 20+ Year Treasury Bond ETF NASDAQ:TLT$86.40 -0.62 (-0.71%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$86.49 +0.09 (+0.10%) As of 08/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares 20+ Year Treasury Bond ETF (the Fund) is an exchange-traded fund. The Fund seeks to track the investment results of an index composed of United States Treasury bonds with remaining maturities greater than 20 years. The Fund seeks to track the investment results of the Barclays U.S. 20+ Year Treasury Bond Index (the Underlying Index), which measures the performance of public obligations of the United States Treasury that have a remaining maturity of 20 or more years. The Underlying Index includes all publicly-issued the United States Treasury securities that have a remaining maturity of greater than or equal to 20 years. BlackRock Fund Advisors serves as investment adviser of the Fund.VentriPoint Diagnostics CVE:VPTC$0.11 -0.01 (-4.35%) As of 08/15/2025 03:55 PM EasternVentripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients. Ventripoint Diagnostics Ltd. is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access